Sex: F
Vaccine: COVID19
Symptoms: Electromyogram, Investigation, Magnetic resonance imaging, Nerve conduction studies, Neuralgic amyotrophy
Clinical narrative: Parsonage-Turner Syndrome; This is a literature report.  A 36-year-old female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: NEURALGIC AMYOTROPHY (medically significant) with onset 2021, 1 week after the suspect product(s) administration, outcome "recovering", described as "Parsonage-Turner Syndrome". The patient underwent the following laboratory tests and procedures: Electromyogram: (2021) Unknown results; electrodiagnostic (EDX) studies: (2021) Fibrillations, positive sharp waves (PSWs), notes: and loss of motor units in right biceps, deltoid, infraspinatus; normal pattern in other muscles including cervical paraspinals Right upper trunk brachial plexus; Magnetic resonance imaging: (2021) no abnormalities of the brachial plexus; Nerve conduction studies: (2021) stimulation at the right Erb's point evoked, notes: a small compound muscle action potential with fibrillations over the deltoid, which showed fibrillations and positive sharp waves indicating significant axonal involvement; Physical examination: (2021) Weakness of right deltoid,, notes: biceps, infraspinatus. Therapeutic measures were taken as a result of neuralgic amyotrophy.  Clinical Course: The patient received COVID-19 1st dose Pfizer vaccine 1 week before right arm symptoms. The symptoms arose on the ipsilateral side to the injection site. The presenting symptoms were right neck and shoulder pain; right arm weak. The physical examination showed weakness of right deltoid, biceps, infraspinatus. The Interval between symptom onset and Electromyography (EMG)/ Nerve Conduction Velocity (NCV) was 5 weeks. The stimulation at the right Erb's point evoked a small compound muscle action potential with fibrillations over the deltoid, which showed fibrillations and positive sharp waves indicating significant axonal involvement. The patient underwent a brachial plexus MRI which revealed no abnormalities of the brachial plexus. The electrodiagnostic (EDX) studies showed Fibrillations, positive sharp waves (PSWs), and loss of motor units in right biceps, deltoid, infraspinatus; normal pattern in other muscles including cervical paraspinals Right upper trunk brachial plexus. The clinical picture coupled with EDX findings supported the diagnosis of PTS. The treatment included prednisone, gabapentin and physical therapy (PT). The arm pain and weakness improved 3 months after onset.  Follow-up (10Aug2023): This is a literature report. This is a follow-up report based on the receipt of the publication; the case has been updated to include additional information identified in the publication.  Updated information included: Reporter and literature information, lab test, event details (onset date, onset latency, seriousness, treatment) and clinical course.; Sender's Comments: Based on the information provided, a causal relationship between suspect drug BNT162B2 and event Neuralgic amyotrophy cannot be excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-202300173553 same article/drug/event and different patient;US-PFIZER INC-202300173551 same article/drug/event and different patient;US-PFIZER INC-202300276122 same article/drug/event and different patient;